GERO Cohort Protocol, Chile, 2017-2022: Community-based Cohort of Functional Decline in Subjective Cognitive Complaint elderly.
Alzheimer
Cognitive aging
Dementia
Functional decline
Geroscience
Subjective cognitive complaint
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
25 11 2020
25 11 2020
Historique:
received:
19
05
2020
accepted:
03
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
9
2
2021
Statut:
epublish
Résumé
With the global population aging and life expectancy increasing, dementia has turned a priority in the health care system. In Chile, dementia is one of the most important causes of disability in the elderly and the most rapidly growing cause of death in the last 20 years. Cognitive complaint is considered a predictor for cognitive and functional decline, incident mild cognitive impairment, and incident dementia. The GERO cohort is the Chilean core clinical project of the Geroscience Center for Brain Health and Metabolism (GERO). The objective of the GERO cohort is to analyze the rate of functional decline and progression to clinical dementia and their associated risk factors in a community-dwelling elderly with subjective cognitive complaint, through a population-based study. We also aim to undertake clinical research on brain ageing and dementia disorders, to create data and biobanks with the appropriate infrastructure to conduct other studies and facilitate to the national and international scientific community access to the data and samples for research. The GERO cohort aims the recruitment of 300 elderly subjects (> 70 years) from Santiago (Chile), following them up for at least 3 years. Eligible people are adults not diagnosed with dementia with subjective cognitive complaint, which are reported either by the participant, a proxy or both. Participants are identified through a household census. The protocol for evaluation is based on a multidimensional approach including socio-demographic, biomedical, psychosocial, neuropsychological, neuropsychiatric and motor assessments. Neuroimaging, blood and stool samples are also obtained. This multidimensional evaluation is carried out in a baseline and 2 follow-ups assessments, at 18 and 36 months. In addition, in months 6, 12, 24, and 30, a telephone interview is performed in order to keep contact with the participants and to assess general well-being. Our work will allow us to determine multidimensional risks factors associated with functional decline and conversion to dementia in elderly with subjective cognitive complain. The aim of our GERO group is to establish the capacity to foster cutting edge and multidisciplinary research on aging in Chile including basic and clinical research. NCT04265482 in ClinicalTrials.gov. Registration Date: February 11, 2020. Retrospectively Registered.
Sections du résumé
BACKGROUND
With the global population aging and life expectancy increasing, dementia has turned a priority in the health care system. In Chile, dementia is one of the most important causes of disability in the elderly and the most rapidly growing cause of death in the last 20 years. Cognitive complaint is considered a predictor for cognitive and functional decline, incident mild cognitive impairment, and incident dementia. The GERO cohort is the Chilean core clinical project of the Geroscience Center for Brain Health and Metabolism (GERO). The objective of the GERO cohort is to analyze the rate of functional decline and progression to clinical dementia and their associated risk factors in a community-dwelling elderly with subjective cognitive complaint, through a population-based study. We also aim to undertake clinical research on brain ageing and dementia disorders, to create data and biobanks with the appropriate infrastructure to conduct other studies and facilitate to the national and international scientific community access to the data and samples for research.
METHODS
The GERO cohort aims the recruitment of 300 elderly subjects (> 70 years) from Santiago (Chile), following them up for at least 3 years. Eligible people are adults not diagnosed with dementia with subjective cognitive complaint, which are reported either by the participant, a proxy or both. Participants are identified through a household census. The protocol for evaluation is based on a multidimensional approach including socio-demographic, biomedical, psychosocial, neuropsychological, neuropsychiatric and motor assessments. Neuroimaging, blood and stool samples are also obtained. This multidimensional evaluation is carried out in a baseline and 2 follow-ups assessments, at 18 and 36 months. In addition, in months 6, 12, 24, and 30, a telephone interview is performed in order to keep contact with the participants and to assess general well-being.
DISCUSSION
Our work will allow us to determine multidimensional risks factors associated with functional decline and conversion to dementia in elderly with subjective cognitive complain. The aim of our GERO group is to establish the capacity to foster cutting edge and multidisciplinary research on aging in Chile including basic and clinical research.
TRIAL REGISTRATION
NCT04265482 in ClinicalTrials.gov. Registration Date: February 11, 2020. Retrospectively Registered.
Identifiants
pubmed: 33238908
doi: 10.1186/s12877-020-01866-4
pii: 10.1186/s12877-020-01866-4
pmc: PMC7690082
doi:
Substances chimiques
Membrane Glycoproteins
0
Receptors, Immunologic
0
Banques de données
ClinicalTrials.gov
['NCT04265482']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
505Subventions
Organisme : Consejo Nacional de Innovación, Ciencia y Tecnología
ID : 15150012
Organisme : Consejo Nacional de Innovación, Ciencia y Tecnología
ID : 1170010
Organisme : Consejo Nacional de Innovación, Ciencia y Tecnología
ID : 1171200
Organisme : NIA NIH HHS
ID : R01 AG057234
Pays : United States
Organisme : FONCyT-PICT
ID : 1818
Organisme : FONCyT-PICT
ID : 1820
Organisme : Consejo Nacional de Innovación, Ciencia y Tecnología (UY)
ID : 15150012
Organisme : Global Brain Health Institute
ID : 20-639295
Organisme : REDI
ID : 170583
Références
J Pers Soc Psychol. 1995 Oct;69(4):719-27
pubmed: 7473027
PLoS One. 2013 Dec 30;8(12):e84014
pubmed: 24386324
Alzheimers Dement. 2018 Mar;14(3):271-279
pubmed: 29028481
Psychol Aging. 2003 Dec;18(4):896-905
pubmed: 14692874
Alzheimers Dement. 2017 Sep;13(9):1031-1047
pubmed: 28576507
Neurodegener Dis Manag. 2016 Jun;6(3):203-13
pubmed: 27229914
NeuroRehabilitation. 2015;37(4):677-98
pubmed: 26639929
Neurologia. 2020 Mar;35(2):82-88
pubmed: 28865943
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Gerontol. 1982 May;37(3):323-9
pubmed: 7069156
Arch Neurol. 2012 Jun;69(6):700-8
pubmed: 22312163
Neurology. 2005 Dec 13;65(11):1817-9
pubmed: 16344531
J Am Geriatr Soc. 2012 Sep;60(9):1708-12
pubmed: 22985143
Arch Neurol. 2007 May;64(5):725-30
pubmed: 17502472
Philos Trans R Soc Lond B Biol Sci. 2009 Oct 27;364(1532):2985-90
pubmed: 19770150
J Am Geriatr Soc. 1985 Apr;33(4):228-35
pubmed: 3989183
Rev Med Chil. 2009 Oct;137(10):1273-82
pubmed: 20011933
J Alzheimers Dis. 2019;67(1):381-392
pubmed: 30584142
Alzheimers Dement. 2015 May;11(5):549-60
pubmed: 25282381
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
PLoS One. 2019 Jul 5;14(7):e0203246
pubmed: 31276468
PLoS Med. 2017 Mar 21;14(3):e1002254
pubmed: 28323826
Neurotoxicol Teratol. 2001 Sep-Oct;23(5):421-30
pubmed: 11711244
Dement Neuropsychol. 2014 Oct-Dec;8(4):317-322
pubmed: 29213920
NeuroRehabilitation. 2015;37(4):639-61
pubmed: 26639932
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Neurology. 2000;54(11 Suppl 5):S16-20
pubmed: 10854356
J Am Geriatr Soc. 2005 Nov;53(11):1966-72
pubmed: 16274380
Lancet. 2008 Aug 9;372(9637):464-74
pubmed: 18657855
Dement Geriatr Cogn Disord. 2016;41(3-4):137-45
pubmed: 26910258
Alzheimers Dement. 2013 Jan;9(1):63-75.e2
pubmed: 23305823
BMC Med Inform Decis Mak. 2019 Jul 9;19(1):128
pubmed: 31288818
Curr Opin Psychiatry. 2012 Nov;25(6):445-50
pubmed: 23037961
Am J Alzheimers Dis Other Demen. 2016 May;31(3):194-200
pubmed: 26340961
Value Health. 2011 Dec;14(8):1135-41
pubmed: 22152184
Neurodegener Dis. 2017;17(4-5):227-234
pubmed: 28719891
J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M28-34
pubmed: 7814786
Dement Geriatr Cogn Disord. 2012;33(6):361-71
pubmed: 22797087
Neurologia. 2019 Jul - Aug;34(6):376-385
pubmed: 28364958
Dement Geriatr Cogn Disord. 2006;22(1):87-94
pubmed: 16710088
Cortex. 2015 Jun;67:83-94
pubmed: 25913063
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Neuropsychology. 2008 Jul;22(4):531-44
pubmed: 18590364
J Am Geriatr Soc. 2008 Jan;56(1):37-44
pubmed: 18028344
Int Psychogeriatr. 2014 Jul;26(7):1067-81
pubmed: 24524645
Rev Med Chil. 2000 Nov;128(11):1199-204
pubmed: 11347506
Popul Stud (Camb). 2009 Nov;63(3):203-13
pubmed: 19851933
J Consult Psychol. 1955 Oct;19(5):393-4
pubmed: 13263471
Alzheimers Res Ther. 2017 Aug 29;9(1):67
pubmed: 28851447
J Am Geriatr Soc. 2009 Nov;57(11):2118-24
pubmed: 20121955
Nat Rev Neurol. 2014 Nov;10(11):620-33
pubmed: 25287597
Am J Psychiatry. 2015 Apr;172(4):323-34
pubmed: 25698435
J Alzheimers Dis. 2017;56(3):929-938
pubmed: 28059789
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Int Psychogeriatr. 2016 Mar;28(3):503-10
pubmed: 26478578
Curr Alzheimer Res. 2015;12(5):493-502
pubmed: 26017560
NeuroRehabilitation. 2015;37(4):515-61
pubmed: 26639930
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S63-86
pubmed: 26402085
Psychogeriatrics. 2017 Jul;17(4):224-230
pubmed: 28130814
Dement Geriatr Cogn Disord. 2007;24(3):185-92
pubmed: 17641531
Arch Clin Neuropsychol. 2016 Mar;31(2):165-75
pubmed: 26758367
Rev Med Chil. 2010 Aug;138(8):1063-5
pubmed: 21140067
Alzheimers Dement. 2011 May;7(3):293-9
pubmed: 21575870
PLoS Med. 2017 Mar 14;14(3):e1002252
pubmed: 28291781
Neuroscience. 1994 Aug;61(4):745-54
pubmed: 7838374
Clin Neuropsychol. 2014;28(2):215-36
pubmed: 24502686
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4299-303
pubmed: 7753801
J Am Geriatr Soc. 2017 Feb;65(2):415-420
pubmed: 27991652
Alzheimers Dement. 2019 Feb;15(2):292-312
pubmed: 30555031
Brain Imaging Behav. 2014 Mar;8(1):1-6
pubmed: 24078043
J Gerontol A Biol Sci Med Sci. 2008 Oct;63(10):1089-96
pubmed: 18948560
Alzheimers Dement. 2017 Dec;13(12):1337-1344
pubmed: 28586648
Alzheimers Dement (Amst). 2016 Oct 14;4:159-168
pubmed: 27830173
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Health Syst Reform. 2017 Oct 2;3(4):253-260
pubmed: 30359182
J Int Neuropsychol Soc. 2009 Sep;15(5):777-86
pubmed: 19635178
J Nutr Health Aging. 2012 Jul;16(7):601-8
pubmed: 22836700
J Am Geriatr Soc. 1986 Feb;34(2):119-26
pubmed: 3944402
PLoS One. 2014 Jul 22;9(7):e102632
pubmed: 25050711
Front Aging Neurosci. 2017 Jul 13;9:221
pubmed: 28751861
Neurosci Lett. 2009 Jan 2;449(1):1-5
pubmed: 18977410
Neurology. 2018 Jan 30;90(5):222-231
pubmed: 29305437
Schizophr Res. 1991 Dec;6(1):25-30
pubmed: 1786233
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Neurology. 2010 Jun 1;74(22):1760-7
pubmed: 20410465
Mol Syst Biol. 2017 Dec 14;13(12):960
pubmed: 29242367
Nat Neurosci. 2016 Dec;19(12):1569-1582
pubmed: 27694991
J Pers Soc Psychol. 1987 Jan;52(1):81-90
pubmed: 3820081
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Alzheimers Dement. 2016 Aug;12(8):909-16
pubmed: 27103260
J Neurol. 2010 Jul;257(7):1160-9
pubmed: 20162428
Neuropsychologia. 2012 Jul;50(8):2075-84
pubmed: 22609573
J Alzheimers Dis. 2018;61(2):589-600
pubmed: 29226861
Neuropsychiatr. 2019 Mar;33(1):35-45
pubmed: 30328583
Neurology. 2006 Dec 12;67(11):1942-8
pubmed: 17159098
Am J Alzheimers Dis Other Demen. 2016 Mar;31(2):105-14
pubmed: 26142292
Front Neurol. 2019 Jul 16;10:756
pubmed: 31379711
Brain. 2008 Nov;131(Pt 11):2957-68
pubmed: 18829698
J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1234-1241
pubmed: 27172939